Open AccessAssociation Between Cytomegalovirus and Epstein-Barr Virus Viremia And Human Immunodeficiency Virus DNA Levels in the Reservoir of Kenyan Infants Receiving Antiretroviral Therapy
Author(s) -
Jennifer A. Slyker,
Brandon L. Guthrie,
Mark D Pankau,
Kenneth Tapia,
Dalton Wamalwa,
Sarah BenkiNugent,
Evelyn Ngugi,
MeeiLi Huang,
Irene Njuguna,
Agnes Langat,
Grace JohnStewart,
Dara A. Lehman
Publication year - 2020
Publication title -
the journal of infectious diseases (online. university of chicago press)/the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jiaa640
Subject(s) - viremia , virology , cytomegalovirus , immunology , human cytomegalovirus , virus , viral load , lentivirus , epstein–barr virus , herpesviridae , medicine , biology , viral disease
Identifying determinants of human immunodeficiency virus (HIV) reservoir levels may inform novel viral eradication strategies. Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) coinfections were assessed as predictors of HIV proviral DNA level in 26 HIV RNA-suppressed Kenyan children starting antiretroviral therapy before 7 months of age. Earlier acquisition of CMV and EBV and higher cumulative burden of systemic EBV DNA viremia were each associated with higher HIV DNA level in the reservoir after 24 months of antiretroviral therapy, independent of HIV RNA levels over time. These data suggest that delaying or containing CMV and EBV viremia may be novel strategies to limit HIV reservoir formation.